Halberd News

Press releases and updates on our medical breakthroughs.

Mar 23 2021

Halberd Corporation Completes Compilation of Medical Articles in Support of Nutraceuticals in Their VITA-SHIELD-MAX(TM) Immune Booster

By |2021-09-28T10:28:40-04:00March 23rd, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 23, 2021 – Halberd Corporation (OTC-PINK: "HALB") has compiled a number of third party published articles from various medical publications which support the selection of the various nutraceuticals in Halberd’s VITA-SHIELD-MAXTM Immune Booster. William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, “After reviewing numerous peer reviewed articles from ...

Read More
Mar 18 2021

Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application Covering Extracorporeal Treatment of COVID-19 and Other Medical Maladies

By |2021-03-17T21:09:58-04:00March 18th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 18, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, “Method for Treating and Curing Covid-19 Infection.”  The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously. William A. ...

Read More
Mar 16 2021

Halberd Corporation Starts VITA-SHIELD-MAX(TM) Immunity Boosting Nutraceutical Production

By |2021-03-15T18:53:11-04:00March 16th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 16, 2021 – Halberd Corporation (OTC PINK:HALB) has contracted with a major nutraceutical manufacturer to produce its initial production lot of Halberd’s VITA-SHIELD-MAXTM Immune Booster.  Halberd’s scientists designed this proprietary combination of vitamins and minerals to help the body increase its natural immunity and promote general health. Dr. Patricio Reyes, Halberd ...

Read More
Mar 11 2021

Halberd Corporation Files VITA-SHIELD-MAX(TM) Trademark For Immunity Boosting Nutraceutical

By |2021-03-10T19:37:28-05:00March 11th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 11, 2021 – Halberd Corporation (OTC PINK:HALB) has filed for trademark protection for the name VITA-SHIELD-MAXTM for its proprietary blend of over-the-counter nutraceuticals designed to boost the body’s immunity and generally enhance health. William A. Hartman, Chairman, President & CEO of Halberd Corp., stated, “We are pleased to be able to ...

Read More
Mar 9 2021

Halberd Corporation’s CEO Interviewed on “The Stock Day Podcast” – Focus on Halberd’s New 20x Affinity Neutralizing SARS-COV-2 Antibody

By |2021-03-08T20:35:16-05:00March 9th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 9, 2021 – Halberd Corporation’s (OTC PINK:HALB) Chairman, President & CEO, William A. Hartman, was interviewed recently on The Stock Day Podcast, hosted by Everett Jolly.  In the interview, Mr. Hartman reviewed the company’s progress in developing SARS-CoV-2 spike protein antibodies and how they can be combined with other Halberd technologies ...

Read More
Mar 2 2021

Halberd’s 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater

By |2021-03-01T20:05:18-05:00March 2nd, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 2, 2021 – Halberd Corp. (OTC PINK:HALB) has recently produced a proprietary monoclonal antibody that has at least 20 times greater neutralizing affinity than their original antibody against the SARS-COV 2 Spike protein. Dr. Reyes, Halberd’s Chief Technical Officer, indicated, “Our latest results indicate increased specificity of our second antibody, which ...

Read More
Feb 16 2021

Halberd Collaborates With GreenBioAZ, Inc. For the Development of Its Patent Pending Radio Frequency Technology to Eliminate Disease Pathogens

By |2021-02-15T21:23:39-05:00February 16th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, February 16, 2021 – Halberd Corp. (OTC PINK:HALB) has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate infectious disease pathogens.  The methodology entails treating bodily fluids with an Antibody-Metallic Moiety Conjugate (AMMC) which targets a specific pathogen such as SARS-CoV-2 during extracorporeally ...

Read More
Feb 1 2021

Halberd Corporation’s CEO Interviewed on The Stock Day Podcast and on MoneyTV

By |2021-01-31T19:36:34-05:00February 1st, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, February 1, 2021 – Halberd Corporation’s (OTC PINK:HALB) Chairman, President & CEO, William A. Hartman, was interviewed recently on The Stock Day Podcast, hosted by Everett Jolly, and on MoneyTV, hosted by Don Baillargeon.  In each interview, Mr. Hartman reviewed the company’s progress on developing SARS-CoV-2 spike protein antibodies which could be ...

Read More
Jan 28 2021

Halberd Corporation Discusses Qualitative & Quantitative Diagnostic Methodology for Detecting COVID-19 Antibodies and Antigens with The Stock Day Podcast

By |2021-01-28T08:45:25-05:00January 28th, 2021|Featured, Investor News, News|0 Comments

Halberd Corporation Discusses Qualitative & Quantitative Diagnostic Methodology for Detecting COVID-19 Antibodies and Antigens with The Stock Day Podcast   Phoenix, AZ January 28th, 2021 (Newsfile Corp.) -- The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB) ("the Company"), a company with a patented extracorporeal treatment applicable to many hard-to-cure blood-borne and neurological diseases, ...

Read More
Jan 14 2021

Halberd Corp. Develops Medication to Boost Immune System Against SARS-CoV-2 (Covid-19)

By |2021-01-13T18:47:16-05:00January 14th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, January 14, 2021 – Halberd Corp. (OTC PINK: "HALB") announced the filing of a provisional patent application on a proprietary combination of nutritional supplements (melatonin, zinc and Vitamin D) combined with low dose Naltrexone designed to reduce the severity of Covid-19 symptoms.  This proprietary combination of nutritional supplements is based on numerous ...

Read More
INVESTOR/MEDIA INQUIRIES

MEDICAL METAVERSE

As part of our efforts to remain at the forefront of breakthrough technologies in the medical and scientific fields, Halberd Corporation is engaged in scientific study and research in the fields of medicine, the prevention, treatment and management of illness and infections and rapid tests to identify infection, and other medical maladies.

To learn more about how we can further your efforts, or to partner with Halberd on specific healthcare solutions, please email: info@halberdcorporation.com

Go to Top